Page last updated: 2024-09-05

arimoclomol and Fabry Disease

arimoclomol has been researched along with Fabry Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arenz, C; Atkins, J; Begley, D; Bornæs, C; Drndarski, S; Gray, J; Hinsby, A; Ingemann, L; Jäättelä, M; Jørgensen, SH; Kirkegaard, T; Klein, A; Morris, L; Olsen, OD; Petersen, NH; Platt, FM; Priestman, DA; Smith, DA; Wallom, KL; Williams, I	1

Other Studies

1 other study(ies) available for arimoclomol and Fabry Disease

Article	Year
Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Science translational medicine, 2016, 09-07, Volume: 8, Issue:355 Topics: Administration, Intravenous; Animals; Blood-Brain Barrier; Bone Morphogenetic Proteins; Disease Models, Animal; Disease Progression; Fabry Disease; Fibroblasts; Glycosphingolipids; Heat-Shock Proteins; Humans; Hydroxylamines; Injections, Intraperitoneal; Intracellular Signaling Peptides and Proteins; Lysosomes; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Proteins; Recombinant Proteins; Sphingolipidoses; Tissue Distribution	2016

Article

Year

Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses.

Science translational medicine, 2016, 09-07, Volume: 8, Issue:355

Topics: Administration, Intravenous; Animals; Blood-Brain Barrier; Bone Morphogenetic Proteins; Disease Models, Animal; Disease Progression; Fabry Disease; Fibroblasts; Glycosphingolipids; Heat-Shock Proteins; Humans; Hydroxylamines; Injections, Intraperitoneal; Intracellular Signaling Peptides and Proteins; Lysosomes; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Proteins; Recombinant Proteins; Sphingolipidoses; Tissue Distribution

2016